Condition: Polycythemia Vera · Sponsor: iOMEDICO AG
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.
This description comes directly from the study's public registry record.
Laura Serrer · +49 761 15242-0 · rope@iomedico.com
Always discuss trial participation with your own doctor first.
| Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde | Hanover, Lower Saxony, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06743035